Comparing the dosages of lacosamide, eslicarbazepine acetate, and controlled-release carbamazepine in noninferiority epilepsy monotherapy trials: How much "fair" is "fair"?
- PMID: 29604068
- DOI: 10.1111/epi.14035
Comparing the dosages of lacosamide, eslicarbazepine acetate, and controlled-release carbamazepine in noninferiority epilepsy monotherapy trials: How much "fair" is "fair"?
Comment in
-
Response: Comparing the dosages of lacosamide, eslicarbazepine acetate, and controlled-release carbamazepine in noninferiority epilepsy monotherapy trials: How much "fair" is "fair".Epilepsia. 2018 Apr;59(4):900-901. doi: 10.1111/epi.14062. Epilepsia. 2018. PMID: 29604066 No abstract available.
Comment on
-
Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.Epilepsia. 2018 Feb;59(2):479-491. doi: 10.1111/epi.13993. Epub 2018 Jan 25. Epilepsia. 2018. PMID: 29369348 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
